IRON SUCROSE INJECTION USP 20 MG
Iron Sucrose Injection is indicated for the treatment of iron deficiency in the following indications:
• Where there is a clinical need for a rapid iron supply,
• In patients who cannot tolerate oral iron therapy or who are non-compliant,
• In active inflammatory bowel disease where oral iron preparations are ineffective,
• In chronic kidney disease when oral iron preparations are less effective.
The diagnosis of iron deficiency must be based on appropriate laboratory tests (e.g. Hb, serum ferritin, TSAT, serum iron, etc.).
(Hb haemoglobin, TSAT transferrin saturation)
Each ml contains:
Ferric Hydroxide in complex with Sucrose
Equivalent to Elemental Iron …20 mg
Method of administration: I.V Injection
Iron Sucrose Injection must only be administered by the intravenous route. This may be by a slow intravenous injection, by an intravenous drip infusion or directly into the venous line of the dialysis machine.
The most commonly reported adverse drug reaction in clinical trials with Iron Sucrose Injection was dysgeusia, which occurred with a rate of 4.5 events per 100 subjects. The most important serious adverse drug reactions associated with Iron Sucrose Injection are hypersensitivity reactions, which occurred with a rate of 0.25 events per 100 subjects in clinical trials. Anaphylactoid/anaphylactic reactions were reported only in the post-marketing setting (estimated as rare); fatalities have been reported.
Iron Sucrose Injection is not recommended for use in children.
Parenterally administered iron preparations can cause hypersensitivity reactions including serious and potentially fatal anaphylactic/anaphylactoid reactions. Hypersensitivity reactions have also been reported after previously uneventful doses of parenteral iron complexes including iron sucrose.
Iron sucrose injection of 5 ml solution is available in one ampoule (type I flint glass) in pack sizes of 5.